Polikistik over sendromunda insülin rezistansı ve nöropeptid Y düzeyleri arasındaki ilişkinin araştırılması
Amaç: Çalışmanın amacı, polikistik over sendromu (PKOS)patogenezinde önemli yeri olan nöropeptid Y (NPY) ve insülindirenci arasındaki ilişkinin araştırılmasıdır.Gereçler ve Yöntemler: Bu çalışma Mayıs 2012 ve Mayıs 2013tarihleri arasında yapılmıştır. Çalışmaya doğurganlık çağındaki 45PKOS hastası ve 44 sağlıklı kontrol grubu dahil edilmiştir. PKOSgrubuna erken foliküler fazda insulin, açlık kan şekeri, folikülstimüle edici hormon (FSH), luteize edici hormon (LH), prolaktin,testesteron, dehidroepiandrosteron sülfat (DHEA-S), tiroidstimüle edici hormon (TSH), kortizol, östrodiol ve NPY düzeyleribakılırken, kontrol grubuna insülin, açlık kan şekeri, prolaktin,DHEA-S, TSH, kortizol, 17-OH progesteron düzeyleri incelendi.Homeostatik model insulin direnci değerlendirme (HOMA-IR)testi skorları hesaplandı ve antropometrik ölçümler kaydedildi.Pelvik ultrasonografi yapıldı.Bulgular: İnsulin direncini gösteren açlık kan insülin düzeyive HOMA-IR skoru, obez PKOS grubunda normal kilolu PKOSve kontrol grubuna göre yüksek bulundu. NPY düzeyleri obezyüksekkilolu PKOS grubunda normal kilolu PKOS ve kontrolgrubuna göre yüksek bulundu ancak istatistiksel olarak anlamlıdeğildi (P>0,05). NPY düzeyleri insülin rezistansı olan ve olmayanhastalar arasında değişiklik göstermedi.Sonuç: İnsülin rezistansı ve NPY düzeyleri arasındakorelasyon saptanmadı ancak NPY düzeyleri, kilolu PCOShastalarında yüksekti.
Investigation of the relationship between insulin resistance and neuropeptide Y levels in polycystic ovary syndrome
Objective: The aim of study is to investigate the relationship between neuropeptide Y (NPY) and insulin resistance which is important in the pathogenesis of poliycstic ovary syndrome (PCOS). Material and Methods: This study was conducted between May 2012 and May 2013. The study included 45 patients with PCOS and 44 healthy controls at productive age. Insulin, fasting blood sugar, follicle-stimulating hormone (FSH), luteinizing hormone (LH), prolactine, testestorone, dehydroepiandrosterone sulfate (DHEA-S), thyroid stimulating hormone (TSH), cortisole, estradiol, NPY levels were measured at early follicular phase in patients with PCOS while insulin, fasting blood sugar, prolactine, DHEA-S, TSH, cortisole, 17-OH progesterone levels were measured in control group. Homeostatic model assessment for insulin resistance (HOMA-IR) scores were calculated and antrepometric measures recorded. Pelvic ultrasonography was performed. Results: Fasting insulin levels and HOMA-IR scores showed insulin resistance to be higher in obese patients with PCOS than healthy control subjects and patients with normal weight PCOS. NPY levels found to be higher in obese-overweight patients with PCOS than healthy control subjects and patients with normal weight but it was not statistically significant (P>0.05). NPY levels did not differ in patients with and without insulin resistance. Conclusion: No correlation dedected between insülin resistance and NPY levels but NPY levels were high in overweight PCOS patients.
___
- 1. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med
2005;352:1223-36. doi:10.1056/NEJM200.506.303522620
- 2. Tsilchorozidou T, Overton C, Conway GS. The
pathophysiology of polycystic ovary syndrome. Clin
Endocrinol Rev 2004; 60:1-17. doi:10.1046/j.1365-
2265.2003.01842.x
- 3. Kayaalp O. Tıbbi Farmakoloji. Cilt:2 9. Baskı. Ankara:
Hacettepe Taş Kitabevi, 2000.
- 4. Herzog, H. Neuropeptide Y and energy homeostasis: insights
from Y receptor knockout models. Eur J Pharmacol 2003;
48:21-9. doi:10.1016/j.ejphar.2003.08.089
- 5. Azziz R, Carmina E, Dewailly D, et al. The Androgen Excess
and PCOS Society criteria for the polycystic ovary syndrome:
the complete task force report. Fertil Steril 2009;91:456-88.
doi: 10.1016/j.fertnstert.2008.06.035.
- 6. The Rotterdam ESHRE/ASRM-Sponsered PCOS Workshop
Group. Revised 2003 consensus on diagnostic criteria
and long-term health risks related to polycystic ovary
syndrome. Fertil Steril 2004; 81:19-25. doi:10.1016/j.
fertnstert.2003.10.004
- 7. Bayram F, Ünlühızarcı K, Kelestimur F. Potential utility
of insulin sensitizers in the treatment of polycystic
ovary syndrome. Treat Endocrinol 2002;1:45-53.
doi:10.2165/00024.677.200201010-00005
- 8. Dunaif A. Insulin resistance and the polycystic
ovary syndrome: mechanism and implications for
pathogenesis. Endocr Rev 1997;18:774-800. doi:10.1210/
edrv.18.6.0318
- 9. Barbieri RL, Ryan KJ. Hyperandrogenism, insulin
resistance, and acanthosis nigricans syndrome: a common
endocrinopathy with distinct pathophysiologic features. Am
J Obstet Gynecol 1983; 147: 90-101. doi:10.1016/0002-
9378(83)90091-1
- 10. Poretsky L, Kalin MF. The gonadotropic function of insulin.
Endocr Rev 1987; 8:132-41. doi:10.1210/edrv-8-2-132
- 11. Poretsky L. On the paradox of insulin-induced
hyperandrogenism in insulin-resistant states. Endocr Rev
1991; 12:3-13. doi:10.1210/edrv-12-1-3
- 12. Tsilchorozidou T, Overton C, Convay SG. The Pathophysiology
of polycystic ovary syndrome. Clin Endocrinol 2004; 60:1-
28. doi:10.1046/j.1365-2265.2003.01842.x
- 13. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound
peripheral insulin resistance, independent of obesity in
polycystic ovary syndrome. Diabetes 1989;38:1165-74.
doi:10.2337/diab.38.9.1165
- 14. Dunaif A, Segal KR, Shelley DR, et al. Evidence for
dinstinctive and intrinsic defect in insulin action in
polycystic ovary syndrome. Diabetes 1992;41:1257-66.
doi:10.2337/diab.41.10.1257
- 15. Dunaif A, Kandarakis DE. New perspectives in polycystic
ovary syndrome. Trends Endocrinol Metab 1996;7: 267-71.
doi:10.1016/S1043-2760(96)00125-7
- 16. Carmina E, Koyama T, Chang L, et al. Does ethnicity
influence the prevalence of adrenal hyperandrogenism
and insulin resistance in polycystic ovary syndrome? Am
J Obstet Gynecol 1992; 167:1807-12. doi:10.1016/0002-
9378(92)91779-A
- 17. Dale PO, Tanbo T, Vaaler S, Abyholm T. Body weight,
hyperinsulinemia and gonadotropin levels in the polycystic
ovarian syndrome: evidence of two distinct populations.
Fertil Steril 1992; 58: 487-91. doi:10.1016/S0015-
0282(16)55249-2
- 18. Bonora E, Targher G, Alberiche M, et al. Homeostasis
model assessment closely mirrors the glucose clamp
technique in the assessment of insulin sensitivity: studies
in subjects with various degrees of glucose tolerance
and insulin sensitivity. Diabetes Care 2000;23:57-63.
doi:10.2337/diacare.23.1.57
- 19. Herbert CM, Hill GA, Diamond MP. The use of the
intravenous glucose tolerans test to evaluate nonobese
hyperandrogenemic women. Fertil Steril 1990;53: 647-53.
doi:10.1016/S0015-0282(16)53458-X
- 20. Ciaraldi TP, el-Roeiy A, Madar Z, Reichart D, Olefsky
JM, Yen SS. Cellular mechanisms of insulin resistance
in polycystic ovary syndrome. J Clin Endocrinol Metab
1992;75: 557-83. doi:10.1210/jcem.75.2.1322430
- 21. Barber TM, McCarthy M, Wass JA, Franks S. Obesity and
polycystic ovary syndrome. Clinic Endocrinol 2006; 65:135-
45. doi:10.1111/j.1365-2265.2006.02587.x
- 22. Franks S. Polycystic ovary syndrome. N Eng J Med
1995;333:853-61. doi: 10.1056/NEJM199.509.283331307
- 23. Stamets K, Taylor DS, Kunselman A, Demers LM, Pelkman
CL, Legro RS. A randomized trial of the effects of two typesof
short – term hypocaloric diets on weight loss in women with
polycystic ovary syndrome. Fertility and Sterility 2004; 81:
630-37. doi:10.1016/j.fertnstert.2003.08.023
- 24. Douchi T, Ijuin H, Nakamura S, Oki T, Yamamoto S, Nagata
Y. Body fat distrubution in women with polycystic ovary
syndrome. Obstet Gynecol 1995;86:516-19. doi:10.1016/
S0029-7844(95)80008-5
- 25. Lefebvre P, Bringer J, Renard E, Boulet F, Clouet S, Jaffiol
C. Influences of weight, body fat patterning and nutrition
on the manegment of PCOS. Hum Reprod 1997;12:72-81.
doi:10.1093/humrep/12.suppl_1.72
- 26. Kirchengast S, Huber J. Body composition characteristics
and body fat distribution in lean women with polycystic ovary
syndrome. Hum Reprod 2001;16:1255-60. doi:10.1016/j.
fertnstert.2003.08.018
- 27. Good C, Tulchinsky M, Mauger D, Demers LM, Legro RS.
Bone mineral density and body composition in lean women
with polycystic ovary syndrome. Fertil Steril 1999;72:21-5.
doi:10.1016/S0015-0282(99)00203-4
- 28. Lord J, Thomas R, Fox B, Acharya U, Wilkin T. The central
issue? Visceral fat mass is a good marker of insulin resistance
and metabolic disturbance in women with polycystic ovary
syndrome. BJOG 2006;113:1203-9. doi:10.1111/j.1471-
0528.2006.00973.x
- 29. Yücel A, Noyan V, Sagsoz N. The association of serum
androgens and insulin resistance with fat distrubution in
polycystic ovary syndrome. Eur J Obstet Gynecol Reprod
Biol 2006.1;126:81-6. doi:10.1016/j.ejogrb.2005.11.012
- 30. Clark JT, Kalra PS, Crowley WR. Neuropeptide Y and
human pancreatic polypeptide stimulate feeding behavior in
rats. Endocrinology 1984; 115: 427-29. doi:10.1210/endo-
115-1-427
- 31. Arora S, Anubhuti. Role of neuropeptides in appetite
regulation and obesity-a review. Neuropeptides 2006; 40:
375-401. doi:10.1016/j.npep.2006.07.001
- 32. Mircea CN, Lujan ME, Pierson RA. Metabolic fuel and
clinical implications for female production. J Obstet
Gynaecol Can 2007; 29:887-902. doi: 10.1016/S1701-
2163(16)32661-5.
- 33. Zarjevski N, Cusin I, Vettor R, Rohner F, Jeanrenaud
B. Chronic intracerebroventricular neuropeptide Y
administration to normal rats mimics hormonal and metabolic
changes of obesity. Endocrinology 1993;133:1753-8.
doi:10.1210/endo.133.4.8404618
- 34. Zarjevski N, Cusin I, Vettor R, Rohner-Jeanrenaud F,
Jeanrenaud B. Intracerebroventricular administration of
neuropeptide Y to normal rats has divergent effects on
glucose utilization by adipose tissue and skeletal muscle.
Diabetes 1994;43:764-9. doi:10.1007/s001250051
- 35. Bennet WM, Wang ZL, Jong P, et al. Presence of neuropeptide
Y and its messenger ribonucleic acid in human islets:
evidence for a possible paracrine role. J Clin Endocrinol
Metab 1996;81:2117-20. doi:10.1210/jcem.81.6.8964837
- 36. Baranowska B, Radzikowska M, Wasilewska-Dziubinska
E, Kaplinski A, Roguski K, Plonowski A. Neuropeptide
Y, leptin, galanin and insulin in women with polycystic
ovary syndrome. Gynecol Endocrinol 1999;13:344-51.
doi:10.3109/095.135.99909167578
- 37. Gunes M, Bukan N. Examination of angiopoietin-like protein
4, neuropeptide Y, omentin-1 levels of obese and non-obese
patients with polycystic ovary syndrome. Gynecol Endocrinol
2015;31:903-6. doi: 10.3109/09513590.2015.1068285.
- 38. Orbetzova MM, Koleva DI, Mitkov MD, et al. Adipocytokines,
neuropeptide Y and insulin resistance in over-weight women
with gynoid and android of adipose tissue distribution. Folia
Medica 2012:54:22-9. doi:10.2478/v10153.011.0093-7
- 39. Hatch R, Rosenfield RL, Kim MH, Tredway D. Hirsutism:
implications, etiology, and management. Am J Obstet Gynecol
1981;140:815-30. doi: 10.1016/0002-9378(81)90746-8
- 40. Gennarelli G, Holte J, Stridsberg M, Niklasson F, Berne
C, Backstrom T. The counter regulatory response to
hypoglycaemia in women with the polycystic ovary syndrome.
Clin Endocrinol (Oxf) 1997;46:167-74. doi:10.1046/j.1365-
2265.1997.107.0915.x